• DiD (DiDC 18 (5)) Red Fluorescent Probe: Mechanism & Evidenc

  2026-07-20

  DiD (DiDC 18 (5)) is a red fluorescent lipophilic probe for plasma membrane labeling, delivering high-fidelity cell tracking and neuronal tracing with minimal cytotoxicity. This article reviews its mechanisms, benchmarks, and protocol parameters, referencing APExBIO’s B8805 kit.

• Angiotensin II (A1042): Protocols and QC for Vascular Models

  2026-07-19

  Angiotensin II (SKU A1042) enables researchers to model hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy in both cell-based and animal studies. This reagent should be used where precise, reproducible activation of angiotensin receptors is required, but is not intended for diagnostic or clinical therapeutic applications.

• Hydrocortisone (B1951): Technical Guide for Research Workflo

  2026-07-18

  Hydrocortisone is a reference glucocorticoid hormone for modulating glucocorticoid receptor signaling in inflammation model research and stress response mechanism studies. It is best used in well-controlled cell or animal models requiring precise dosing and validated anti-inflammatory pathway modulation. Hydrocortisone should not be used where water- or ethanol-soluble glucocorticoids are mandated or in protocols incompatible with DMSO-based stocks.

• Mildronate-Derived Lipidoids Minimize mRNA Vaccine Inflammat

  2026-07-17

  A 2024 ACS Nano study introduces mildronate-derived cationic lipidoids as a novel, low-dose component for mRNA lipid nanoparticles, achieving efficient vaccine delivery with markedly reduced inflammatory side effects. These findings offer a promising route to safer, more effective mRNA vaccine and immunogen research in preclinical and translational settings.

• Vancomycin Hydrochloride: Strategic Leverage in Translationa

  2026-07-17

  Explore the mechanistic power and translational strategy of Vancomycin hydrochloride as a benchmark glycopeptide antibacterial agent. This thought-leadership article offers in-depth biological context, protocol recommendations, and evidence-driven insights for translational researchers tackling antibiotic resistance, with direct links to the latest workflows and comparative studies. By bridging rigorous mechanistic understanding with forward-looking strategy, this piece guides researchers toward reproducible, high-impact results in both preclinical models and clinical translation.

• Lin28B/Let-7/PBK Axis Targeting in TNBC: Ponicidin as a Dual

  2026-07-16

  This study identifies Lin28B as a TNBC-specific target, elucidates ponicidin’s dual inhibitory and degradation mechanism on the Lin28B/Let-7/PBK axis, and demonstrates tumor suppression in vitro and in vivo. These findings provide a foundation for novel targeted strategies in triple-negative breast cancer.

• Sisomicin and Related Aminoglycosides: Activity and Clinical

  2026-07-16

  This review article synthesizes comparative data on Sisomicin, netilmicin, and dibekacin, highlighting Sisomicin’s broad-spectrum antibacterial activity, mechanisms of resistance, and clinical utility. The analysis underscores Sisomicin’s marginal efficacy advantages over gentamicin and tobramycin, its pharmacokinetics, and the strategic considerations for research and clinical application in Gram-negative infections.

• Applied Workflows with GDC-0068 (RG7440) for Akt Pathway Inh

  2026-07-15

  GDC-0068 (RG7440) enables precise, isoform-selective inhibition of the PI3K/Akt/mTOR pathway, making it indispensable for dissecting spatially controlled signaling events in tumor models. This guide details practical workflows, optimization strategies, and troubleshooting tips, uniquely bridging recent advances in mTORC1 compartmentalization with actionable bench protocols.

• Vancomycin Hydrochloride in Advanced Infection Models and Ti

  2026-07-15

  Explore the multifaceted applications of Vancomycin hydrochloride as a glycopeptide antibacterial agent, with a focus on its role in sophisticated infection assays and regenerative tissue engineering. This in-depth review uniquely bridges experimental microbiology and translational organ bioengineering.

• Mithramycin A: Advanced Workflows in Cancer Biology Research

  2026-07-14

  Mithramycin A stands apart as an anticancer antibiotic that precisely targets G-C-rich DNA, enabling selective inhibition of oncogenic transcription in cancer and cardiac disease models. This article delivers an integrated workflow, practical protocol parameters, and troubleshooting strategies, directly leveraging new mechanistic insights from Sp1/PI3K axis research.

• dKeap1-Lamin Interaction Regulates Chromatin Architecture in

  2026-07-14

  This study uncovers a direct molecular interaction between Drosophila Keap1 (dKeap1) and B-type lamin (lamin Dm0), revealing a novel mechanism by which the Keap1-Nrf2 pathway can regulate nuclear architecture and chromatin organization. The work provides foundational insights into how oxidative/xenobiotic response factors impact heterochromatin structure and gene expression, offering new avenues for developmental and nuclear biology research.

• Position 3 Pyridylalanine Modification in GnRH Antagonists

  2026-07-13

  This study explores the synthesis and biological profiling of degarelix analogs with novel 3-(2-methoxy-5-pyridyl)-alanine substitutions at position 3, revealing how stereochemistry alters receptor binding and in vivo duration. Findings refine our understanding of structure-activity relationships in GnRH receptor antagonists, with implications for prostate cancer and hormone regulation research.

• Z-IETD-FMK: Precision Caspase-8 Inhibition for T Cell Studie

  2026-07-13

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise inhibition of caspase-8, transforming T cell proliferation and apoptosis assays. Discover advanced workflows, troubleshooting insights, and comparative advantages for apoptosis and immune signaling research using this high-specificity tool.

• BIBR 1532: Redefining Telomerase Inhibition in Cancer Assays

  2026-07-12

  Explore how BIBR 1532, a potent telomerase inhibitor, advances cancer research with unparalleled specificity. Delve into its unique molecular mechanism and practical assay implications not covered in prior literature.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-10

  Schwartz's dissertation introduces a conceptual and methodological advance in evaluating anti-cancer drug responses in vitro by distinguishing proliferative arrest from cell death. This distinction enhances accuracy in preclinical cancer studies, allowing for more reproducible and interpretable data when testing agents such as polyether ionophore antibiotics.

453 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page